Multidisciplinary treatment strategies for the assessment of immune, coagulation, and biomarker responses after transarterial chemoembolization for hepatocellular carcinoma

Table 1 Comparative analysis of participant characteristics between the two groups

	Experimental group (n = 45)	Control group (n = 44)	χ2/t	P value
Gender, male/female	35 (77.78)/10 (22.22)	37 (84.09)/7 (15.91)	0.574	0.449
Age, years	61.55 ± 9.53	62.34 ± 10.34	0.375	0.709
BMI, kg/m2	24.03 ± 1.37	24.12 ± 1.65	0.280	0.780
NRS2002 score	2.86 ± 0.87	2.79 ± 1.03	0.347	0.730
Maximum tumor diameter, cm	5.79 ± 1.54	6.03 ± 1.48	0.749	0.456
BCLC staging, A/B/C	8 (17.78)/32(71.11)/ 5 (11.11)	7 (15.91)/35 (79.55)/2(4.55)	1.437	0.541
Liver function Child-Pugh grading, A/B	39 (86.67)/6 (13.33)	41 (93.18)/3 (6.82)		0.485
Smoking history, yes/no	29 (64.44)/16 (35.56)	33 (75.00)/11 (25.00)	1.173	0.279
Alcohol history, yes/no	27 (60.00)/18 (40.00)	32 (72.73)/12 (17.27)	1.613	0.204
Tumor family history, yes no	13 (28.89)/32 (71.11)	14 (31.82)/30 (68.18)	0.090	0.764
Chronic underlying disease, yes/no	26 (57.78)/19 (42.22)	23 (52.27)/11 (47.73)	0.801	0.371

Results expressed as means ± SD, or n (%). BMI: Body mass index; NRS2002: Nutritional Risk Score 2002; BCLC: Barcelona Clinic Liver Cancer.